



New Advances on Zika Virus Research

Guest Editors:

Dr. Luis Martinez-Sobrido

Department of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA

luis_martinez@
urmc.rochester.edu

Dr. Fernando Almazan Toral

Department of Molecular and Cell Biology, National Center for Biotechnology, Darwin 3, 28049 Madrid, Spain

falmazan@cnb.csic.es

Deadline for manuscript
submissions:

closed (30 September 2018)

Message from the Guest Editors

Dear Colleagues,

Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family that has been known to cause sporadic outbreaks in Africa and Southeast Asia. Recently, ZIKV has been associated with Guillain-Barre syndrome and microcephaly in the infants of infected mothers, a condition where infants are born with abnormally-small heads. To date, there are no Food and Drug Administration (FDA)-licensed prophylactics (vaccines) or therapeutics (antivirals) available for the treatment of ZIKV disease in humans, which has the potential to affect millions of people worldwide. The significance of ZIKV in human health, together with the limited existing armamentarium to combat ZIKV infection, highlight the importance of developing effective countermeasures to prevent or treat ZIKV infection in humans. In this Special Issue, we will focus on the most recent discoveries in ZIKV research, including the molecular biology of the virus, virus–host interactions, antivirals, and vaccine development.

Dr. Luis Martinez-Sobrido
Dr. Fernando Almazan Toral
Guest Editors





Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and
Replication Program, Center for
Cancer Research, National
Cancer Institute, Frederick, MD
21702-1201, USA

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section. Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the **Science Citation Index Expanded** (Web of Science), **MEDLINE** (PubMed) and other databases. Full-text available in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.4 days after submission; acceptance to publication is undertaken in 4.1 days (median values for papers published in this journal in the second half of 2018).

Contact Us
